Accendra Health Inc (ACH) Fair Value & Analysis
Healthcare · US · Market cap $238M · ISIN US6907321029
Risks
Fair value as of: Aug 13, 2026
From 3 valuation models · updated 15 days ago
Fair value updated Aug 13, 2026, revised from $2.21 to $0.9944 (−55.0%) since Jul 14, 2026. Share price −62.8% over the past month.
Below-average quality, and trading another 22% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($0.9944). The favourable scenario is already priced in.
- Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.9500 – $48.31 · fair‑value band $0.5917 – $0.9944 · the $1.21 price screens above the $0.9944 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Accendra Health Inc (ACH) currently trades at $1.21, while our model-based Fair Value estimate is $0.9944, implying the stock looks roughly 17.8% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Accendra Health Inc generated revenue of $2.7B at a net margin of -39.8%. Revenue declined 6.8% year over year. Net debt stands at $2.0B. Fundamentals as of Aug 13, 2026
Our scenario range runs from $0.5917 (bear case) to $0.9944 (bull case); at $1.21, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -9% fair-value upside, at -18%, ACH screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Notify me when ACH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 38 · Market factors (momentum, volatility) 5
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous …
Full company description
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Accendra Health Inc reported revenue of $2.8B in FY2025 versus $9.8B in FY2021, a compound −27.1%/yr. Reported net income was −$1.1B in FY2025.
ACH screens 18% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $896.65 | $819.31 | -9% |
| Cencora, Inc COR | $327.79 | $211.07 | -36% |
| Cardinal Health, Inc CAH | $238.40 | $141.77 | -41% |
| Henry Schein, Inc HSIC | $88.46 | $71.70 | -19% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.37 | ¥33.96 | +107% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | -24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.03 | ¥28.65 | +36% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 74.40 | kr 28.26 | -62% |
Compare Accendra Health Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Accendra Health Inc (ACH) overvalued or undervalued?
What is the fair value of ACH?
What is the quality score of ACH?
What is the revenue of Accendra Health Inc (ACH)?
What is the net profit margin of ACH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Accendra Health Inc in the live analysis
One click puts Accendra Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.